XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.

XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.
G
G

GSK

뉴스

Reuters - 3 일 전

EMA Approves GSK's Arexvy For Adults Aged 50-59 At Increased Risk

BRIEF-EMA Approves GSK's Arexvy For Adults Aged 50-59 At Increased Risk Aug 29 (Reuters) - GSK plc GSK.L : GSK PLC - EMA APPROVAL ON AREXVY FOR 50-59 AT RISK GSK PLC - EMA APPROVAL ON AREXVY FOR 50-59 AT RISK GSK PLC - FILED REGULATORY SUBMISSIONS TO EXTEND AREXVY USE TO ADULTS 50-59 IN JAPAN AND OTHER GEOGRAPHIES Source text for Eikon: ID:nRSc0515
G
Reuters - 4 일 전

UK Stocks-Factors to watch on Aug 28

UPDATE 1-UK Stocks-Factors to watch on Aug 28 Adds new items, updates futures Aug 28 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Wednesday, with futures FFIc1 up 0.2%. * FRASERS: British sportswear and apparel retailer Frasers FRAS.L said it has purchased a 14.65% stake in Australian sportswear retailer Accent Group Ltd. * FCA: Britain's Financial Conduct Authority said it would launch a market study into pure protection insurance product sales, amid fears that the desig
G
U
Reuters - 4 일 전

GSK Says Bepirovirsen granted SENKU designation in Japan

BRIEF-GSK Says Bepirovirsen granted SENKU designation in Japan Aug 28 (Reuters) - GSK plc GSK.L : SENKU DESIGNATION FOR BEPIROVIRSEN IN JAPAN CONFIRMATORY PHASE III PROGRAMME B-WELL ONGOING Source text for Eikon: ID:nRSb8953Ba Further company coverage: GSK.L
G
Reuters - 4 일 전

GSk's Nucala Approved In Japan For Use In CRSwNP

BRIEF-GSk's Nucala Approved In Japan For Use In CRSwNP Aug 28 (Reuters) - GSK plc GSK.L : GSK PLC - NUCALA APPROVED IN JAPAN FOR USE IN CRSWNP GSK: MEPOLIZUMAB IS APPROVED IN JAPAN TO TREAT BRONCHIAL ASTHMA IN CHILDREN AGED 6-YEAR OR OLDER AND IN ADULTS WITH REFRACTORY ASTHMA Source text for Eikon: ID:nRSb9634Ba Further company coverage: GSK.L
G
Reuters - 4 일 전

UK Stocks-Factors to watch on Aug 28

UK Stocks-Factors to watch on Aug 28 Aug 28 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Wednesday, with futures FFIc1 up 0.1%. * GSK: Delaware's highest court said it will hear an appeal by GSK GSK.L and other drugmakers seeking to end more than 70,000 lawsuits claiming discontinued heartburn drug Zantac caused cancer. * PRUDENTIAL: Prudential PRU.L reported an 9% rise in first-half operating profit, backed by a strong rebound of new sales in Hong Kong after the removal
B
G
U
Reuters - 4 일 전

British Business - Aug 28

PRESS DIGEST-British Business - Aug 28 Aug 28 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - Delaware's highest court will hear an appeal by GSK GSK.L and rival drugmakers seeking to end more than 70,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer .
B
E
G
H
N
Reuters - 4 일 전

Delaware top court will hear drugmakers' appeal to end Zantac lawsuits

UPDATE 3-Delaware top court will hear drugmakers' appeal to end Zantac lawsuits Adds response from plaintiffs' attorneys in paragraph 5 By Brendan Pierson Aug 27 (Reuters) - Delaware's highest court said on Tuesday it will hear an appeal by GSK GSK.L and other drugmakers seeking to end more than 70,000 lawsuits claiming discontinued heartburn drug Zantac caused cancer.
G
P
S
Reuters - 4 일 전

Delaware top court will hear drugmakers' appeal to end Zantac lawsuits

Delaware top court will hear drugmakers' appeal to end Zantac lawsuits Aug 27 (Reuters) - Delaware's highest court said on Tuesday it will hear an appeal by GSK GSK.L and other drugmakers seeking to end more than 70,000 lawsuits claiming discontinued heartburn drug Zantac caused cancer. GSK, Pfizer PFE.N , Sanofi SASY.PA and Boehringer Ingelheim are asking the court to overturn an order by a lower court judge allowing plaintiffs in the lawsuits to offer expert testimony on the alleged cancer lin
G
P
S
Reuters - 6 일 전

British Business - Aug. 26

PRESS DIGEST-British Business - Aug. 26 Aug 26 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - The British Financial Conduct Authority has warned unregulated firms that they cannot help to arrange investment deals for private companies without regulatory permissions.
A
G
M
Reuters - 1 주 전

Ozempic on Wall Street's list for 2027 Medicare drug negotiations

ANALYSIS-Ozempic on Wall Street's list for 2027 Medicare drug negotiations Novo Nordisk, Pfizer, GSK drugs likely to be in 2027 Medicare negotiations Most drugs already discounted, limited impact seen on Big Pharma Analysts expect price cuts to have bigger bite starting in 2028 By Michael Erman NEW YORK, Aug 23 (Reuters) - Now that the U.S. government has negotiated prices for some Medicare program drugs effective in 2026 , Wall Street analysts are betting on a 2027 list that will include Novo N
G
P
T
Reuters - 2 주 전

GSK Gets FDA Breakthrough Therapy Designation For GSK5764227

BRIEF-GSK Gets FDA Breakthrough Therapy Designation For GSK5764227 Aug 20 (Reuters) - GSK plc GSK.L : GSK PLC - B7-H3 ADC US FDA BREAKTHROUGH THERAPY DESIGNATION GSK PLC - RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR GSK5764227 Source text for Eikon: ID:nRST0175Ba Further company coverage: GSK.L
G
Reuters - 2 주 전

GSK to seek dismissal of Florida case against heartburn drug Zantac

GSK to seek dismissal of Florida case against heartburn drug Zantac Aug 16 (Reuters) - British drugmaker GSK GSK.L said on Friday it would seek a dismissal of an upcoming Zantac case in Florida, where plaintiffs alleged that its discontinued heart burn drug had caused prostate cancer. The move followed a Florida court ruling on Thursday in favour of GSK and other defendants.
G
P
S
Reuters - 2 주 전

GSK Says Florida Court Rules In Favor Of GSK In Zantac Litigation

BRIEF-GSK Says Florida Court Rules In Favor Of GSK In Zantac Litigation Aug 16 (Reuters) - GSK plc GSK.L : STATEMENT: ZANTAC (RANITIDINE) LITIGATION FLORIDA COURT RULES IN FAVOR OF GSK IN ZANTAC LITIGATION WELCOMES FLORIDA STATE COURT DAUBERT RULING CONTINUES TO DEFEND ITSELF INCLUDING AGAINST ALL REMAINING CLAIMS IN OTHER JURISDICTIONS Source text
G
Reuters - 3 주 전

German panel endorses GSK, Pfizer RSV vaccines for elderly

German panel endorses GSK, Pfizer RSV vaccines for elderly FRANKFURT, Aug 8 (Reuters) - Germany's influential vaccine advisory panel said on Thursday that everyone in the country who is 75-years old or more should receive one of two new vaccines against the common respiratory infection RSV. The panel of independent experts known as STIKO said in a statement that one shot, either Pfizer's PFE.N Abrysvo or Arexvy by GSK GSK.L , should be administered ideally in September or October before the cold
A
G
P
S
Reuters - 3 주 전

UK Stocks-Factors to watch on August 8

UPDATE 1-UK Stocks-Factors to watch on August 8 Adds new items, updates futures Aug 8 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Thursday, with futures FFIc1 down 0.3%. * BARRATT-REDROW DEAL: UK's competition regulator said its phase 1 review into homebuilder Barratt's BDEV.L 2.52 billion pound ($3.21 billion) all-stock deal to buy smaller rival Redrow RDW.L had raised concerns in the local area around a Barratt development.
A
A
B
B
B
B
F
G
I
I
P
P
R
R
S
S
Reuters - 3 주 전

UK Stocks-Factors to watch on August 8

UK Stocks-Factors to watch on August 8 Aug 8 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Thursday, with futures FFIc1 down 0.5%. * GSK: The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial when jurors could not agree about whether pharmaceutical company Boehringer Ingelheim was responsible for an Illinois man's cancer.
A
A
B
B
B
D
F
G
H
I
I
L
P
P
P
R
S
S
U
Reuters - 3 주 전

Third trial over Zantac cancer claims ends with hung jury

UPDATE 1-Third trial over Zantac cancer claims ends with hung jury Adds response from plaintiff's attorney in paragraphs 2-3 By Brendan Pierson Aug 7 (Reuters) - The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial on Wednesday when jurors could not agree about whether pharmaceutical company Boehringer Ingelheim was responsible for an Illinois man's cancer.
G
P
S
Reuters - 3 주 전

Third trial over Zantac cancer claims ends with hung jury

Third trial over Zantac cancer claims ends with hung jury By Brendan Pierson Aug 7 (Reuters) - The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial on Wednesday when jurors could not agree about whether pharmaceutical company Boehringer Ingelheim was responsible for an Illinois man's cancer, according to the plaintiff's lawyer.
G
P
S
Reuters - 3 주 전

Drugmaker Abbott India's Q1 profit climbs on higher sales, price hikes

Drugmaker Abbott India's Q1 profit climbs on higher sales, price hikes BENGALURU, Aug 7 (Reuters) - Drugmaker Abbott India ABOT.NS reported a rise in first-quarter profit on Wednesday, helped by higher sales and price hikes. The company, which makes the popular antacid medicine Digene, said its profit rose to 3.28 billion rupees ($39.1 million) for the quarter ended June 30, a 13% rise from last year.
A
G
P
Reuters - 4 주 전

Jefferies cuts SOBI to 'hold' as competition weighs

BUZZ-Jefferies cuts SOBI to 'hold' as competition weighs ** Jefferies cuts Swedish Orphan Biovitrum SOBIV.ST to "hold" from "buy", citing increasing competition pressure for the Swedish drug maker ** Brokerage sees Merck's MRK.N positive data for antibody against lung infections caused by respiratory syncytial virus (RSV), clesrovimab, as a downsid
G
S

조건

인기 자산

면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.

온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.

이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.

리스크 경고: 고객님의 자본이 위험에 노출 될 수 있습니다. 레버리지 상품은 모든 분들에게 적합하지 않을수 있습니다. 당사의 리스크 공시를 참고하시기 바랍니다.